drugset / Trial / NCT00160212

Study to Evaluate the Efficacy and Safety of SLV306 in Subjects With Hypertension

NCT00160212 ↗

Phase 2 Completed Solvay Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is to compare the efficacy and safety of increasing doses of SLV306 with amlodipine.

Timeline

Start
2004-12
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Daglutril Small molecule 150 mg —
Subject Daglutril Small molecule 300 mg —
Subject Daglutril Small molecule 600 mg —

Indications